Despite high hopes, Roche’s anti-amyloid antibody shows no significant benefit in slowing cognitive decline, prompting reevaluation of Alzheimer’s …
Despite high hopes, Roche’s anti-amyloid antibody shows no significant benefit in slowing cognitive decline, prompting reevaluation of Alzheimer’s …
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
A new framework aims to harmonize clinical trial data reporting across borders, boosting transparency and accelerating global drug …
FDA mandates clearer drug ads, Merck expands oncology portfolio, and political shifts raise questions about public health leadership.
Backed by top-tier investors, the new biotech aims to redefine psychiatric care with precision neurotherapeutics
Landmark Series A round positions Australian biotech at the forefront of neurodegenerative disease innovation.
The CGM giant and smart ring innovator join forces to integrate biosensor data and reshape personal health tracking.
Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
